绝经前激素受体阳性乳腺癌辅助内分泌治疗的研究进展  

Progresses in adjuvant endocrine treatment of pre-menopausal patients with breast cancer

作　　者：曾银朵[1] 汪颖[1] 吴雯静[1] 赵健丽[1] 姚和瑞[1] 

机构地区：[1]中山大学孙逸仙纪念医院乳腺肿瘤医学部,广东广州510288

出　　处：《现代肿瘤医学》2016年第15期2466-2470,共5页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81372819;81572596;81502302);教育部博士点基金(编号:20120171110075);广州市科技计划(编号:2014J4100170);中山大学青年教师重点培育项目(编号:13ykzd14)

摘　　要：内分泌治疗是激素受体阳性乳腺癌术后辅助治疗的主要手段之一。对于绝经前患者,术后五年的他莫昔芬(TAM)一直是辅助内分泌治疗的金标准,然而,随着诸多旨在提高辅助内分泌治疗疗效研究的发表与更新,辅助内分泌治疗取得较多的进展。本文围绕绝经前乳腺癌阐述当前辅助内分泌治疗的情况,主要分析他莫昔芬(TAM)、芳香化酶抑制剂(AI)、药物性卵巢功能抑制的地位、它们之间联合的优势人群、药物使用的时限等,探讨绝经前早期乳腺癌辅助内分泌治疗的研究进展。Endocrine therapy is one of the predominant treatments of adjuvant therapy among pre- menopausal patients with hormone receptor- positive breast cancer. Five years after operation adjuvant tamoxifen is still the standard endocrine therapy for the pre- menopausal patients. Many studies and clinical trials contributs to the increased effectiveness of adjuvant endocrine therapy. This article reviews the current progress of endocrine therapy in pre- menopausal patients with special focus on a number of issues,including the role of tamoxifen,aromatase inhibitor,ovarian ablation,combination endocrine therapy,the dorminant crowd of combined therapy,the duration of treatment.

关 键 词：乳腺癌 绝经前 内分泌治疗 卵巢去势 

分 类 号：R737.9[医药卫生—肿瘤]